GIA
EDIT icon

Gladstone Institutional Advisory’s Editas Medicine EDIT Stock Holding History

Gladstone Institutional Advisory’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,661
Closed -$280K – 522
2021
Q1 		$280K Buy
6,661
+3,086
+86% +$176K 0.04% 331
2020
Q4 		$251K Buy
+3,575
New +$147K 0.05% 257

Other funds holding EDIT

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Gladstone Institutional Advisory's EDIT Position: Q2 2021 in Review

Gladstone Institutional Advisory sold out of Editas Medicine (EDIT) in Q2 2021, closing a stake of 6,661 shares — an estimated $280K sold.

Gladstone Institutional Advisory first reported a position in EDIT in Q4 2020 and held it in 2 quarters. The position peaked at $280K in Q1 2021. 313 funds tracked by Wall St. Rank hold EDIT as of Q2 2021.

  • Gladstone Institutional Advisory reported no remaining Editas Medicine position as of Q2 2021 after selling out during the quarter.
  • Gladstone Institutional Advisory sold 6,661 Editas Medicine shares in Q2 2021, an estimated $280K.
  • Gladstone Institutional Advisory first reported a position in Editas Medicine in Q4 2020 and held it in 2 quarters.
  • Gladstone Institutional Advisory's Editas Medicine position peaked at $280K in Q1 2021.
  • 313 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2021.

Based on Gladstone Institutional Advisory's 13F filing for Q2 2021, filed 13 Aug 2021.